drugset / Trial / NCT02186873

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

NCT02186873

Phase 3 Completed 208 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic inflammatory disease of unknown etiology that involves the sacroiliac joints, and often the axial skeleton, entheses, and peripheral joints).

Timeline

Start
2014-09-03
Primary completion
2015-12-15
Completion
2016-10-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 2 mg/kg Intravenous